Veren Inc

VRN

Equity

ISIN CA92340V1076 / Valor 135002270

Toronto Stock Exchange (2024-12-24)

CAD 7.08+2.31%

Veren Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Veren Inc. specializes in developing and commercializing innovative medical devices aimed at improving the treatment of chronic sinusitis.

Summarized from source with an LLMView SourceSector: Energy

Q2 2024 Earnings Miss

Veren Inc reported a significant miss in its earnings per share (EPS) for Q2 2024, with a recorded EPS of -0.66 CAD against an expected 0.36 CAD, resulting in a -280.98% surprise. This shortfall highlights challenges the company faced during the quarter.

Q2 2024 Revenue Shortfall

For Q2 2024, Veren Inc also reported revenue of 936.05 million CAD, which did not meet the analysts' expectations of 1.01 billion CAD. This discrepancy indicates a potential slowdown in sales or operational issues that impacted the company's financial performance.

Future EPS Outlook

Looking ahead to the next quarter, Veren Inc is estimated to achieve an EPS of 0.43 CAD. This forecast suggests a potential recovery or improvement in the company's profitability after a tough Q2 2024.

Revenue Forecast for Next Quarter

Veren Inc's revenue for the upcoming quarter is projected to reach 1.06 billion CAD. This expectation sets a target for the company to aim for better performance and possibly compensate for the previous quarter's shortfall.

Next Earnings Report Date

The next earnings report for Veren Inc is scheduled for July 25, 2024. This date will be crucial for investors and analysts to assess whether the company has managed to turn around its performance for Q3 2024.

Summarized from source with an LLMView Source

Key figures

-24.0%1Y

%3Y

%5Y

Performance

33.3%1Y

33.3%3Y

33.3%5Y

Volatility